{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T00:34:52Z","timestamp":1784334892996,"version":"3.55.0"},"reference-count":59,"publisher":"Impact Journals, LLC","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,4,25]]},"DOI":"10.18632\/oncotarget.15883","type":"journal-article","created":{"date-parts":[[2017,3,4]],"date-time":"2017-03-04T19:26:05Z","timestamp":1488655565000},"page":"28008-28020","source":"Crossref","is-referenced-by-count":14,"title":["An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and <i>TP53<\/i> disruption as predictors of outcome and chemorefractoriness"],"prefix":"10.18632","volume":"8","author":[{"given":"Gian Matteo","family":"Rigolin","sequence":"first","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Formigaro","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cavallari","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Maria","family":"Quaglia","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Lista","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Urso","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Guardalben","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Martinelli","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Saccenti","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Bassi","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, and \u201cLaboratorio per le Tecnologie delle Terapie Avanzate\u201d (LTTA), University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Lupini","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, and \u201cLaboratorio per le Tecnologie delle Terapie Avanzate\u201d (LTTA), University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonella","family":"Bardi","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Volta","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Tammiso","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurora","family":"Melandri","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Negrini","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, and \u201cLaboratorio per le Tecnologie delle Terapie Avanzate\u201d (LTTA), University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cavazzini","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cuneo","sequence":"additional","affiliation":[{"name":"Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","article-title":"Chronic lymphocytic leukemia","volume":"352","author":"Ferrarini","year":"2005","journal-title":"N Engl J Med"},{"key":"2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc2764","article-title":"From pathogenesis to treatment of chronic lymphocytic leukaemia","volume":"10","author":"Stilgenbauer","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Shanafelt. Predicting clinical outcome in CLL: how and why. Hematology Am Soc Hematol Educ Program. 2009; pp. 421\u2013429.","DOI":"10.1182\/asheducation-2009.1.421"},{"key":"4","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/cam4.226","article-title":"Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups","volume":"3","author":"Rigolin","year":"2014","journal-title":"Cancer Med"},{"key":"5","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/ajh.23979","article-title":"Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment","volume":"90","author":"Hallek","year":"2015","journal-title":"Am J Hematol"},{"key":"6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Jacquillat","year":"1981","journal-title":"Cancer"},{"key":"7","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Vinciguerra","year":"1999","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2002-10-3306","article-title":"ZAP70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile","volume":"101","author":"Arthur","year":"2003","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2013.50.8515","article-title":"CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia","volume":"32","author":"Pepper","year":"2014","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Lichter","year":"2000","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Marasca","year":"2013","journal-title":"Blood"},{"key":"12","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Schnittger","year":"2014","journal-title":"Leukemia"},{"key":"13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Kantorova","year":"2015","journal-title":"Leukemia"},{"key":"14","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Catovsky","year":"2013","journal-title":"Blood"},{"key":"15","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial","volume":"123","author":"Hoth","year":"2014","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood-2015-02-585042","article-title":"Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia","volume":"126","author":"Wu","year":"2015","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness","volume":"118","author":"Cerri","year":"2011","journal-title":"Blood"},{"key":"18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Mertens","year":"2015","journal-title":"Nature"},{"key":"19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Juan","year":"2011","journal-title":"Nature"},{"key":"20","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1182\/blood-2013-11-539726","article-title":"Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia","volume":"123","author":"Guarini","year":"2014","journal-title":"Blood"},{"key":"21","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/leu.2014.297","article-title":"Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia","volume":"29","author":"Plevova","year":"2015","journal-title":"Leukemia"},{"key":"22","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.3324\/haematol.2015.136051","article-title":"Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia","volume":"101","author":"De Paoli","year":"2016","journal-title":"Haematologica"},{"key":"23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Eckart","year":"2014","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI working group","year":"2016","journal-title":"Lancet Oncol"},{"key":"25","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1182\/blood-2015-10-620864","article-title":"Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis","volume":"127","author":"Shanafelt","year":"2016","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2141.2008.07227.x","article-title":"Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis","volume":"142","author":"Marasca","year":"2008","journal-title":"Br J Haematol"},{"key":"27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/sj.leu.2403242","article-title":"Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis","volume":"18","author":"Tieghi","year":"2004","journal-title":"Leukemia"},{"key":"28","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2011-11-395269","article-title":"Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with \u201cnormal\u201d FISH: correlations with clinicobiologic parameters","volume":"119","author":"Zaja","year":"2012","journal-title":"Blood"},{"key":"29","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/gcc.22293","article-title":"Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations","volume":"54","author":"Sofritti","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1182\/blood-2016-01-691550","article-title":"Complex karyotypes, KRAS and POT1 mutations impact outcome in CLL after chlorambucil based chemo- or chemoimmunotherapy","volume":"128","author":"D\u00f6hner","year":"2016","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"3612","DOI":"10.1002\/cncr.29566","article-title":"Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens","volume":"121","author":"Keating","year":"2015","journal-title":"Cancer"},{"key":"32","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1038\/sj.leu.2404935","article-title":"Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgHV status and immunophenotyping","volume":"21","author":"Haferlach","year":"2007","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ajh.23618","article-title":"Chromosomal translocations and karyotype complexity in chronic lymphocytic leukemia: a systematic reappraisal of classic cytogenetic data","volume":"89","author":"Belessi","year":"2014","journal-title":"Am J Hematol"},{"key":"34","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1182\/blood-2006-02-005322","article-title":"Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgHV status, and CD38 expression","volume":"108","author":"Schoch","year":"2006","journal-title":"Blood"},{"key":"35","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3324\/haematol.2014.109777","article-title":"Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting","volume":"100","author":"Belessi","year":"2015","journal-title":"Haematologica"},{"key":"36","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1182\/blood-2013-03-488197","article-title":"NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG","volume":"122","author":"Busch","year":"2013","journal-title":"Blood"},{"key":"37","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Marinelli","year":"2012","journal-title":"Blood"},{"key":"38","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Fernandes","year":"2011","journal-title":"N Engl J Med"},{"key":"39","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation","volume":"208","author":"Forconi","year":"2011","journal-title":"J Exp Med"},{"key":"40","first-page":"47","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Navarro","year":"2011","journal-title":"Nat Genet"},{"key":"41","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and impact of subclonal mutations in chronic lymphocytic leukemia","volume":"152","author":"Shukla","year":"2013","journal-title":"Cell"},{"key":"42","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood-2007-05-092759","article-title":"Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia","volume":"111","author":"Stilgenbauer","year":"2008","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia","volume":"373","author":"McCarthy","year":"2015","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1182\/blood-2015-03-630947","article-title":"A phase 2 study of idelalisib plus rituximab in treatment-na\u00efve older patients with chronic lymphocytic leukemia","volume":"126","author":"Kim","year":"2015","journal-title":"Blood"},{"key":"45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","article-title":"The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype","volume":"23","author":"Haferlach","year":"2009","journal-title":"Leukemia"},{"key":"46","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1182\/blood-2014-07-586826","article-title":"European Research Initiative on CLL (ERIC) and the European Society for Blood and Marrow Transplantation (EBMT). Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?","volume":"124","author":"Montserrat","year":"2014","journal-title":"Blood"},{"key":"47","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","article-title":"De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience","volume":"114","author":"Keating","year":"2009","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"e0143073","DOI":"10.1371\/journal.pone.0143073","article-title":"A low frequency of losses in 11q chromosome is associated with better outcome and lower rate of genomic mutations in patients with chronic lymphocytic leukemia","volume":"10","author":"Gonz\u00e1lez","year":"2015","journal-title":"PLoS One"},{"key":"49","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-016-0320-z","article-title":"Extensive Next Generation Sequencing analysis in Chronic Lymphocytic Leukemia at diagnosis: clinical and biological correlations","volume":"9","author":"Melandri","year":"2016","journal-title":"J Hematol Oncol"},{"key":"50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/ajh.23668","article-title":"Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients","volume":"89","author":"Brugiatelli","year":"2014","journal-title":"Am J Hematol"},{"key":"51","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1182\/blood-2015-05-647925","article-title":"Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"key":"52","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S2352-3026(16)30064-3","article-title":"Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial","volume":"3","author":"Conte","year":"2016","journal-title":"Lancet Haematol"},{"key":"53","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Mobasher","year":"2016","journal-title":"Lancet Oncol"},{"key":"54","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Kipps","year":"2008","journal-title":"Blood"},{"key":"55","first-page":"1640","article-title":"The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL","volume":"8","author":"Catovsky","year":"1994","journal-title":"Leukemia"},{"key":"56","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/cncr.24961","article-title":"Circulating endothelial cells in patients with chronic lymphocytic leukemia: clinical-prognostic and biologic significance","volume":"116","author":"Cuneo","year":"2010","journal-title":"Cancer"},{"key":"57","first-page":"691493","article-title":"Employment of oligodeoxynucleotide plus interleukin-2 improves cytogenetic analysis in splenic marginal zone lymphoma","volume":"2011","author":"D\u2019Auria","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"58","doi-asserted-by":"publisher","first-page":"140","DOI":"10.18632\/oncotarget.1382","article-title":"Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients","volume":"5","author":"Cavazzini","year":"2014","journal-title":"Oncotarget"},{"key":"59","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","article-title":"The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness","volume":"15","author":"Gaidano","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T18:43:53Z","timestamp":1589136233000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.15883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":59,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2017,4,25]]}},"alternative-id":["15883","28427204"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.15883","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}